Loading...
32 colchicine COVID-19 controlled studies, 16 RCTs
38% improvement, RR
0.62
[0.52-0.73]
https://c19colchicine.com/meta.html
0
0.5
1
1.5+
All studies
38%
32
22,499
Improvement, Studies, Patients
Relative Risk
Mortality
40%
27
20,771
Ventilation
42%
5
12,575
ICU admission
30%
4
576
Hospitalization
23%
10
6,815
Progression
81%
3
289
Recovery
30%
9
12,419
Cases
-73%
1
1,278
RCTs
22%
16
18,820
RCT mortality
9%
13
18,438
Peer-reviewed
41%
29
21,978
Prophylaxis
26%
3
1,278
Late
39%
29
21,221
Colchicine for COVID-19
c19colchicine.com May 2022
Favors colchicine
Favors control
after exclusions
• Statistically significant improvements are seen for
mortality ,
ICU admission ,
hospitalization , and
recovery . 20 studies from 20 independent teams in 13 different countries show statistically significant
improvements in isolation (11 for the most serious outcome).
• Results are robust — in exclusion sensitivity analysis 22 of 32
studies must be excluded to avoid finding statistically significant efficacy
in pooled analysis.
0
0.5
1
1.5+
All studies
38%
32
22,499
Improvement, Studies, Patients
Relative Risk
Mortality
40%
27
20,771
Ventilation
42%
5
12,575
ICU admission
30%
4
576
Hospitalization
23%
10
6,815
Progression
81%
3
289
Recovery
30%
9
12,419
Cases
-73%
1
1,278
RCTs
22%
16
18,820
RCT mortality
9%
13
18,438
Peer-reviewed
41%
29
21,978
Prophylaxis
26%
3
1,278
Late
39%
29
21,221
Colchicine for COVID-19
c19colchicine.com May 2022
Favors colchicine
Favors control
after exclusions
• RCT results are less favorable, however they are dominated by the very late stage RECOVERY RCT,
for which the results are not generalizable to earlier usage.
• While many treatments have some level
of efficacy, they do not replace vaccines and other measures to avoid
infection.
Only 16% of colchicine
studies show zero events in the treatment arm.
Multiple treatments are typically used
in combination, and
other treatments
may be more effective.
There has been no early treatment studies to date.
• No treatment, vaccine, or intervention is 100%
available and effective for all variants. All practical, effective, and safe
means should be used.
Denying the efficacy of treatments increases mortality, morbidity, collateral
damage, and endemic risk.
• All data to reproduce this paper and
sources are in the
appendix .
Other meta analyses for colchicine can be found in
[Yasmin , Zein ] , showing significant improvements for mortality and severity.
Highlights
We show traditional outcome specific analyses and combined
evidence from all studies, incorporating treatment delay, a primary
confounding factor in COVID-19 studies.
A
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT)
77%
0.23 [0.03-1.97]
death
1/55
4/50
Improvement, RR [CI]
Treatment
Control
Lopes (DB RCT)
80%
0.20 [0.01-4.03]
death
0/36
2/36
Brunetti (PSM)
73%
0.27 [0.08-0.89]
death
3/33
11/33
Scarsi
85%
0.15 [0.06-0.37]
death
122 (n)
140 (n)
Salehzadeh (RCT)
23%
0.77 [0.66-0.90]
hosp. time
50 (n)
50 (n)
Pinzón
35%
0.65 [0.34-1.21]
death
14/145
23/156
Sandhu
42%
0.58 [0.40-0.85]
death
16/34
63/78
Rodriguez-Nava
6%
0.94 [0.61-1.47]
death
16/52
85/261
Mahale
-7%
1.07 [0.59-1.96]
death
11/39
25/95
Valerio Pas.. (ICU)
23%
0.77 [0.31-1.94]
death
5/35
12/30
ICU patients CT1
Tardif (DB RCT)
44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
Mareev
80%
0.20 [0.01-4.01]
death
0/21
2/22
García-Posada
57%
0.43 [0.16-0.84]
death
48/99
59/110
CT1
Manenti (PSW)
76%
0.24 [0.09-0.67]
death
71 (n)
70 (n)
Mostafaie (RCT)
83%
0.17 [0.02-1.34]
death
1/60
6/60
CT1
Recovery C.. (RCT)
-1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
Hueda-Zavaleta
54%
0.46 [0.23-0.91]
death
10/50
109/301
Kevorkian
96%
0.04 [0.01-0.21]
progression
28 (n)
40 (n)
CT1
Gaitán-Dua.. (RCT)
22%
0.78 [0.44-1.36]
death
22/153
28/161
CT1
Pascual-Fi.. (RCT)
80%
0.20 [0.01-4.03]
death
0/52
2/51
Dorward (RCT)
70%
0.30 [0.01-7.37]
death
0/156
1/120
Absalón-.. (DB RCT)
29%
0.71 [0.21-2.40]
death
4/56
6/60
Diaz (RCT)
12%
0.88 [0.70-1.12]
death
131/640
142/639
Alsultan (RCT)
36%
0.64 [0.20-2.07]
death
3/14
7/21
Karakaş
13%
0.87 [0.46-1.64]
death
16/165
19/171
Pourdowlat (RCT)
73%
0.27 [0.11-0.71]
hosp.
5/102
18/100
Gorial (RCT)
67%
0.33 [0.04-3.14]
death
1/80
3/80
Pimenta B.. (RCT)
79%
0.21 [0.01-4.05]
death
0/14
2/16
Jalal (RCT)
24%
0.76 [0.62-0.93]
hosp. time
36 (n)
44 (n)
Tau2 = 0.10, I2 = 74.4%, p < 0.0001
Late treatment
39%
0.61 [0.50-0.73]
1,485/10,243
1,828/10,978
39% improvement
Monserrat V.. (PSM)
80%
0.20 [0.02-0.93]
death
n/a
n/a
Improvement, RR [CI]
Treatment
Control
Topless
23%
0.77 [0.56-1.07]
death
Oztas
-406%
5.06 [0.59-43.2]
hosp.
5/635
1/643
Tau2 = 0.86, I2 = 69.7%, p = 0.66
Prophylaxis
26%
0.74 [0.21-2.66]
5/635
1/643
26% improvement
All studies
38%
0.62 [0.52-0.73]
1,490/10,878
1,829/11,621
38% improvement
32 colchicine COVID-19 studies
c19colchicine.com May 2022
Tau2 = 0.10, I2 = 73.4%, p < 0.0001
Effect extraction pre-specified (most serious outcome, see appendix)
1 CT: study uses combined treatment
Favors colchicine
Favors control
B
C
Figure 1. A. Random effects
meta-analysis. This plot shows pooled effects, discussion can be found in the heterogeneity section,
and results for specific outcomes can be found in the individual outcome analyses.
Effect extraction is pre-specified, using the most serious outcome reported.
For details of effect extraction see the
appendix .
B. Scatter plot showing the
distribution of effects reported in studies.
C. History of all reported
effects (chronological within treatment stages).
Introduction
We analyze all significant studies
concerning the use of
colchicine
for COVID-19.
Search methods, inclusion criteria, effect
extraction criteria (more serious outcomes have priority), all individual
study data, PRISMA answers, and statistical methods are detailed in
Appendix 1 . We present random effects meta-analysis results for all
studies, for studies within each treatment stage, for individual outcomes, for
peer-reviewed studies, for Randomized Controlled Trials (RCTs), and after
exclusions.
Figure 2 shows stages of possible treatment for
COVID-19.
Prophylaxis refers to regularly taking medication before
becoming sick, in order to prevent or minimize infection.
Early
Treatment refers to treatment immediately or soon after symptoms appear,
while
Late Treatment refers to more delayed treatment.
Results
Figure 3 shows a visual overview of the results, with details in
Table 1 and
Table 2 .
Figure
4 ,
5 ,
6 ,
7 ,
8 ,
9 ,
10 ,
11 , and
12
show forest plots for a random effects meta-analysis of
all studies with pooled effects, mortality results, ventilation, ICU admission, hospitalization, progression, recovery, cases, and peer reviewed studies.
0
0.5
1
1.5+
ALL STUDIES
MORTALITY
VENTILATION
ICU ADMISSION
HOSPITALIZATION
PROGRESSION
RECOVERY
CASES
RCTS
RCT MORTALITY
PEER-REVIEWED
After Exclusions
ALL STUDIES
All
Prophylaxis
Late
Colchicine for COVID-19
C19COLCHICINE.COM MAY 2022
Treatment time Number of studies reporting positive effects
Total number of studies Percentage of studies reporting positive effects
Random effects meta-analysis results
Late treatment
27
29
93.1%
39% improvement
RR 0.61 [0.50‑0.73]
p < 0.0001
Prophylaxis
2
3
66.7%
26% improvement
RR 0.74 [0.21‑2.66]
p = 0.66
All studies
29
32
90.6%
38% improvement
RR 0.62 [0.52‑0.73]
p < 0.0001
Table 1. Results by treatment stage.
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT)
77%
0.23 [0.03-1.97]
death
1/55
4/50
Improvement, RR [CI]
Treatment
Control
Lopes (DB RCT)
80%
0.20 [0.01-4.03]
death
0/36
2/36
Brunetti (PSM)
73%
0.27 [0.08-0.89]
death
3/33
11/33
Scarsi
85%
0.15 [0.06-0.37]
death
122 (n)
140 (n)
Salehzadeh (RCT)
23%
0.77 [0.66-0.90]
hosp. time
50 (n)
50 (n)
Pinzón
35%
0.65 [0.34-1.21]
death
14/145
23/156
Sandhu
42%
0.58 [0.40-0.85]
death
16/34
63/78
Rodriguez-Nava
6%
0.94 [0.61-1.47]
death
16/52
85/261
Mahale
-7%
1.07 [0.59-1.96]
death
11/39
25/95
Valerio Pas.. (ICU)
23%
0.77 [0.31-1.94]
death
5/35
12/30
ICU patients CT1
Tardif (DB RCT)
44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
Mareev
80%
0.20 [0.01-4.01]
death
0/21
2/22
García-Posada
57%
0.43 [0.16-0.84]
death
48/99
59/110
CT1
Manenti (PSW)
76%
0.24 [0.09-0.67]
death
71 (n)
70 (n)
Mostafaie (RCT)
83%
0.17 [0.02-1.34]
death
1/60
6/60
CT1
Recovery C.. (RCT)
-1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
Hueda-Zavaleta
54%
0.46 [0.23-0.91]
death
10/50
109/301
Kevorkian
96%
0.04 [0.01-0.21]
progression
28 (n)
40 (n)
CT1
Gaitán-Dua.. (RCT)
22%
0.78 [0.44-1.36]
death
22/153
28/161
CT1
Pascual-Fi.. (RCT)
80%
0.20 [0.01-4.03]
death
0/52
2/51
Dorward (RCT)
70%
0.30 [0.01-7.37]
death
0/156
1/120
Absalón-.. (DB RCT)
29%
0.71 [0.21-2.40]
death
4/56
6/60
Diaz (RCT)
12%
0.88 [0.70-1.12]
death
131/640
142/639
Alsultan (RCT)
36%
0.64 [0.20-2.07]
death
3/14
7/21
Karakaş
13%
0.87 [0.46-1.64]
death
16/165
19/171
Pourdowlat (RCT)
73%
0.27 [0.11-0.71]
hosp.
5/102
18/100
Gorial (RCT)
67%
0.33 [0.04-3.14]
death
1/80
3/80
Pimenta B.. (RCT)
79%
0.21 [0.01-4.05]
death
0/14
2/16
Jalal (RCT)
24%
0.76 [0.62-0.93]
hosp. time
36 (n)
44 (n)
Tau2 = 0.10, I2 = 74.4%, p < 0.0001
Late treatment
39%
0.61 [0.50-0.73]
1,485/10,243
1,828/10,978
39% improvement
Monserrat V.. (PSM)
80%
0.20 [0.02-0.93]
death
n/a
n/a
Improvement, RR [CI]
Treatment
Control
Topless
23%
0.77 [0.56-1.07]
death
Oztas
-406%
5.06 [0.59-43.2]
hosp.
5/635
1/643
Tau2 = 0.86, I2 = 69.7%, p = 0.66
Prophylaxis
26%
0.74 [0.21-2.66]
5/635
1/643
26% improvement
All studies
38%
0.62 [0.52-0.73]
1,490/10,878
1,829/11,621
38% improvement
32 colchicine COVID-19 studies
c19colchicine.com May 2022
Tau2 = 0.10, I2 = 73.4%, p < 0.0001
Effect extraction pre-specified (most serious outcome, see appendix)
1 CT: study uses combined treatment
Favors colchicine
Favors control
Figure 4. Random effects meta-analysis for all studies with pooled effects.
This plot shows pooled effects, discussion can be found in the heterogeneity section,
and results for specific outcomes can be found in the individual outcome analyses.
Effect extraction is pre-specified, using the most serious outcome reported.
For details of effect extraction see the
appendix .
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT)
77%
0.23 [0.03-1.97]
1/55
4/50
Improvement, RR [CI]
Treatment
Control
Lopes (DB RCT)
80%
0.20 [0.01-4.03]
0/36
2/36
Brunetti (PSM)
73%
0.27 [0.08-0.89]
3/33
11/33
Scarsi
85%
0.15 [0.06-0.37]
122 (n)
140 (n)
Pinzón
35%
0.65 [0.34-1.21]
14/145
23/156
Sandhu
42%
0.58 [0.40-0.85]
16/34
63/78
Rodriguez-Nava
6%
0.94 [0.61-1.47]
16/52
85/261
Mahale
-7%
1.07 [0.59-1.96]
11/39
25/95
Valerio Pas.. (ICU)
23%
0.77 [0.31-1.94]
5/35
12/30
ICU patients CT1
Tardif (DB RCT)
44%
0.56 [0.19-1.67]
5/2,235
9/2,253
Mareev
80%
0.20 [0.01-4.01]
0/21
2/22
García-Posada
57%
0.43 [0.16-0.84]
48/99
59/110
CT1
Manenti (PSW)
76%
0.24 [0.09-0.67]
71 (n)
70 (n)
Mostafaie (RCT)
83%
0.17 [0.02-1.34]
1/60
6/60
CT1
Recovery C.. (RCT)
-1%
1.01 [0.93-1.10]
1,173/5,610
1,190/5,730
Hueda-Zavaleta
54%
0.46 [0.23-0.91]
10/50
109/301
Gaitán-Dua.. (RCT)
22%
0.78 [0.44-1.36]
22/153
28/161
CT1
Pascual-Fi.. (RCT)
80%
0.20 [0.01-4.03]
0/52
2/51
Dorward (RCT)
70%
0.30 [0.01-7.37]
0/156
1/120
Absalón-.. (DB RCT)
29%
0.71 [0.21-2.40]
4/56
6/60
Diaz (RCT)
12%
0.88 [0.70-1.12]
131/640
142/639
Alsultan (RCT)
36%
0.64 [0.20-2.07]
3/14
7/21
Karakaş
13%
0.87 [0.46-1.64]
16/165
19/171
Gorial (RCT)
67%
0.33 [0.04-3.14]
1/80
3/80
Pimenta B.. (RCT)
79%
0.21 [0.01-4.05]
0/14
2/16
Tau2 = 0.14, I2 = 72.6%, p < 0.0001
Late treatment
40%
0.60 [0.48-0.75]
1,480/10,027
1,810/10,744
40% improvement
Monserrat V.. (PSM)
80%
0.20 [0.02-0.93]
n/a
n/a
Improvement, RR [CI]
Treatment
Control
Topless
23%
0.77 [0.56-1.07]
Tau2 = 0.64, I2 = 71.1%, p = 0.24
Prophylaxis
53%
0.47 [0.13-1.67]
53% improvement
All studies
40%
0.60 [0.49-0.74]
1,480/10,027
1,810/10,744
40% improvement
27 colchicine COVID-19 mortality results
c19colchicine.com May 2022
Tau2 = 0.13, I2 = 72.0%, p < 0.0001
1 CT: study uses combined treatment
Favors colchicine
Favors control
Figure 5. Random effects meta-analysis for mortality results.
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT)
82%
0.18 [0.02-1.50]
1/55
5/50
Improvement, RR [CI]
Treatment
Control
Sandhu
53%
0.47 [0.33-0.67]
16/34
68/68
Tardif (DB RCT)
47%
0.53 [0.25-1.09]
11/2,235
21/2,253
Recovery C.. (RCT)
-18%
1.18 [0.99-1.40]
259/3,815
228/3,962
Pascual-Fi.. (RCT)
80%
0.20 [0.01-4.03]
0/52
2/51
Tau2 = 0.36, I2 = 85.3%, p = 0.12
Late treatment
42%
0.58 [0.30-1.16]
287/6,191
324/6,384
42% improvement
All studies
42%
0.58 [0.30-1.16]
287/6,191
324/6,384
42% improvement
5 colchicine COVID-19 mechanical ventilation results
c19colchicine.com May 2022
Tau2 = 0.36, I2 = 85.3%, p = 0.12
Favors colchicine
Favors control
Figure 6. Random effects meta-analysis for ventilation.
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lopes (DB RCT)
50%
0.50 [0.10-2.56]
2/36
4/36
Improvement, RR [CI]
Treatment
Control
Valerio Pas.. (ICU)
40%
0.60 [0.38-0.95]
35 (n)
30 (n)
ICU patients CT1
Pascual-Fi.. (RCT)
51%
0.49 [0.09-2.56]
2/52
4/51
Karakaş
16%
0.84 [0.55-1.29]
30/165
37/171
Tau2 = 0.00, I2 = 0.0%, p = 0.021
Late treatment
30%
0.70 [0.52-0.95]
34/288
45/288
30% improvement
All studies
30%
0.70 [0.52-0.95]
34/288
45/288
30% improvement
4 colchicine COVID-19 ICU results
c19colchicine.com May 2022
Tau2 = 0.00, I2 = 0.0%, p = 0.021
1 CT: study uses combined treatment
Favors colchicine
Favors control
Figure 7. Random effects meta-analysis for ICU admission.
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lopes (DB RCT)
22%
0.78 [0.64-0.94]
hosp. time
36 (n)
36 (n)
Improvement, RR [CI]
Treatment
Control
Salehzadeh (RCT)
23%
0.77 [0.66-0.90]
hosp. time
50 (n)
50 (n)
Tardif (DB RCT)
20%
0.80 [0.61-1.03]
hosp.
101/2,235
128/2,253
Mareev
26%
0.74 [0.53-1.04]
hosp. time
21 (n)
22 (n)
Mostafaie (RCT)
35%
0.65 [0.53-0.81]
hosp. time
59 (n)
54 (n)
CT1
Pascual-Fi.. (RCT)
-15%
1.15 [0.87-1.51]
hosp. time
52 (n)
51 (n)
Karakaş
25%
0.75 [0.65-0.87]
hosp. time
165 (n)
171 (n)
Pourdowlat (RCT)
73%
0.27 [0.11-0.71]
hosp.
5/102
18/100
Jalal (RCT)
24%
0.76 [0.62-0.93]
hosp. time
36 (n)
44 (n)
Tau2 = 0.01, I2 = 47.1%, p < 0.0001
Late treatment
23%
0.77 [0.69-0.85]
106/2,756
146/2,781
23% improvement
Oztas
-406%
5.06 [0.59-43.2]
hosp.
5/635
1/643
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.14
Prophylaxis
-406%
5.06 [0.59-43.2]
5/635
1/643
-406% improvement
All studies
23%
0.77 [0.69-0.86]
111/3,391
147/3,424
23% improvement
10 colchicine COVID-19 hospitalization results
c19colchicine.com May 2022
Tau2 = 0.01, I2 = 50.2%, p < 0.0001
1 CT: study uses combined treatment
Favors colchicine
Favors control
Figure 8. Random effects meta-analysis for hospitalization.
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT)
87%
0.13 [0.01-0.97]
1/55
7/50
Improvement, RR [CI]
Treatment
Control
Kevorkian
96%
0.04 [0.01-0.21]
28 (n)
40 (n)
CT1
Absalón-.. (DB RCT)
17%
0.83 [0.35-1.93]
56 (n)
60 (n)
Tau2 = 2.47, I2 = 80.7%, p = 0.1
Late treatment
81%
0.19 [0.03-1.38]
1/139
7/150
81% improvement
All studies
81%
0.19 [0.03-1.38]
1/139
7/150
81% improvement
3 colchicine COVID-19 progression results
c19colchicine.com May 2022
Tau2 = 2.47, I2 = 80.7%, p = 0.1
1 CT: study uses combined treatment
Favors colchicine
Favors control
Figure 9. Random effects meta-analysis for progression.
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Brunetti (PSM)
73%
0.27 [0.08-0.89]
no disch.
3/33
11/33
Improvement, RR [CI]
Treatment
Control
Sandhu
42%
0.58 [0.40-0.85]
no disch.
16/34
63/78
Mareev
50%
0.50 [0.24-1.04]
no recov.
21 (n)
22 (n)
Manenti (PSW)
44%
0.56 [0.31-1.00]
no recov.
71 (n)
70 (n)
Recovery C.. (RCT)
-2%
1.02 [0.97-1.06]
no disch.
1,709/5,610
1,698/5,730
Dorward (RCT)
-6%
1.06 [0.81-1.39]
no recov.
156 (n)
133 (n)
Absalón-.. (DB RCT)
-13%
1.13 [0.76-1.66]
no recov.
56 (n)
60 (n)
Pourdowlat (RCT)
38%
0.62 [0.41-0.94]
no recov.
89 (n)
63 (n)
Gorial (RCT)
63%
0.37 [0.21-0.67]
no recov.
80 (n)
80 (n)
Tau2 = 0.10, I2 = 78.1%, p = 0.0085
Late treatment
30%
0.70 [0.54-0.91]
1,728/6,150
1,772/6,269
30% improvement
All studies
30%
0.70 [0.54-0.91]
1,728/6,150
1,772/6,269
30% improvement
9 colchicine COVID-19 recovery results
c19colchicine.com May 2022
Tau2 = 0.10, I2 = 78.1%, p = 0.0085
Favors colchicine
Favors control
Figure 10. Random effects meta-analysis for recovery.
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Oztas
-73%
1.73 [0.96-3.11]
symp. case
29/635
17/643
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.068
Prophylaxis
-73%
1.73 [0.96-3.11]
29/635
17/643
-73% improvement
All studies
-73%
1.73 [0.96-3.11]
29/635
17/643
-73% improvement
1 colchicine COVID-19 case result
c19colchicine.com May 2022
Tau2 = 0.00, I2 = 0.0%, p = 0.068
Favors colchicine
Favors control
Figure 11. Random effects meta-analysis for cases.
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Deftereos (RCT)
77%
0.23 [0.03-1.97]
death
1/55
4/50
Improvement, RR [CI]
Treatment
Control
Lopes (DB RCT)
80%
0.20 [0.01-4.03]
death
0/36
2/36
Brunetti (PSM)
73%
0.27 [0.08-0.89]
death
3/33
11/33
Scarsi
85%
0.15 [0.06-0.37]
death
122 (n)
140 (n)
Sandhu
42%
0.58 [0.40-0.85]
death
16/34
63/78
Rodriguez-Nava
6%
0.94 [0.61-1.47]
death
16/52
85/261
Mahale
-7%
1.07 [0.59-1.96]
death
11/39
25/95
Valerio Pas.. (ICU)
23%
0.77 [0.31-1.94]
death
5/35
12/30
ICU patients CT1
Tardif (DB RCT)
44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
Mareev
80%
0.20 [0.01-4.01]
death
0/21
2/22
García-Posada
57%
0.43 [0.16-0.84]
death
48/99
59/110
CT1
Manenti (PSW)
76%
0.24 [0.09-0.67]
death
71 (n)
70 (n)
Recovery C.. (RCT)
-1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
Hueda-Zavaleta
54%
0.46 [0.23-0.91]
death
10/50
109/301
Kevorkian
96%
0.04 [0.01-0.21]
progression
28 (n)
40 (n)
CT1
Gaitán-Dua.. (RCT)
22%
0.78 [0.44-1.36]
death
22/153
28/161
CT1
Pascual-Fi.. (RCT)
80%
0.20 [0.01-4.03]
death
0/52
2/51
Dorward (RCT)
70%
0.30 [0.01-7.37]
death
0/156
1/120
Absalón-.. (DB RCT)
29%
0.71 [0.21-2.40]
death
4/56
6/60
Diaz (RCT)
12%
0.88 [0.70-1.12]
death
131/640
142/639
Alsultan (RCT)
36%
0.64 [0.20-2.07]
death
3/14
7/21
Karakaş
13%
0.87 [0.46-1.64]
death
16/165
19/171
Pourdowlat (RCT)
73%
0.27 [0.11-0.71]
hosp.
5/102
18/100
Gorial (RCT)
67%
0.33 [0.04-3.14]
death
1/80
3/80
Pimenta B.. (RCT)
79%
0.21 [0.01-4.05]
death
0/14
2/16
Jalal (RCT)
24%
0.76 [0.62-0.93]
hosp. time
36 (n)
44 (n)
Tau2 = 0.14, I2 = 75.9%, p < 0.0001
Late treatment
42%
0.58 [0.47-0.72]
1,470/9,988
1,799/10,712
42% improvement
Monserrat V.. (PSM)
80%
0.20 [0.02-0.93]
death
n/a
n/a
Improvement, RR [CI]
Treatment
Control
Topless
23%
0.77 [0.56-1.07]
death
Oztas
-406%
5.06 [0.59-43.2]
hosp.
5/635
1/643
Tau2 = 0.86, I2 = 69.7%, p = 0.66
Prophylaxis
26%
0.74 [0.21-2.66]
5/635
1/643
26% improvement
All studies
41%
0.59 [0.48-0.73]
1,475/10,623
1,800/11,355
41% improvement
29 colchicine COVID-19 peer reviewed trials
c19colchicine.com May 2022
Tau2 = 0.13, I2 = 74.8%, p < 0.0001
Effect extraction pre-specified (most serious outcome, see appendix)
1 CT: study uses combined treatment